 - Patients with up to 1 prior cytotoxic regimen for metastatic disease will be eligible. There will be no prior limitation on adjuvant therapies for stage IIIII disease or for patients with stage IV disease treated after resection of all metastatic disease. There will be no prior limitation on biological or hormonal therapies immune therapies, interferon, hypomethylating agents, histone deacetylase inhibitors, etc., however, patients previously treated with mTOR inhibitors will be excluded. Prior treatment for metastatic disease is not required. Patients must have recovered from the acute toxicities of prior treatment. Chronic toxicities must have recovered to grade 1. The minimum interval between prior treatment and first day of dosing on this trial is as follows: standard cytotoxic agents and radiation therapy, 21 days; mitomycin and nitrosoureas, 6 weeks; hormonal and immunotherapy agents, 2 weeks; minor surgery, 2 weeks, major surgery, 3 weeks; investigational agents 4-weeks. 